Forest Laboratories, Inc. Enters Collaboration on Bystolic(R) and Savella(R) in Canada

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (Forest) (NYSE: FRX) today announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.